Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 4/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445603 | 0.78 | KDM1A (0.39) | KDM1ADCPSHPGDSJAK1GPR119 | |
| SCHEMBL20160685 | 0.78 | KDM1A (0.39) | KDM1ADCPSHPGDSJAK1GPR119 | |
| SCHEMBL1515165 | 0.77 | HTR2B (0.34) | — | |
| SCHEMBL827042 | 0.76 | KDM1A (0.38) | KDM1ADCPSHPGDSJAK1GPR119 | |
| SCHEMBL20635752 | 0.76 | KDM1A (0.38) | KDM1ADCPSHPGDSJAK1GPR119 | |
| SCHEMBL459481 | 0.76 | GNAI3 (0.39) | KDM1ADCPSHPGDSJAK1GPR119 | |
| SCHEMBL834995 | 0.76 | ACHE (0.43) | KDM1AHPGDSGPR119 | |
| SCHEMBL445604 | 0.76 | KDM1A (0.38) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL25235628 | 0.76 | KDM1A (0.34) | KDM1A | |
| SCHEMBL13713266 | 0.76 | GNAI3 (0.47) | KDM1AHPGDSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | claimed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | claimed |
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | claimed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2021224864-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| WO-2021224865-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| WO-2020229968-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2020-11-19 | — | — | WO | claimed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1565475-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| CN-1171889-C | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase | - | 2004-10-20 | — | — | CN | disclosed |
| WO-2004046152-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN LA ROCHE AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |
| CN-1382144-A | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase | HOFFMANN LA ROCHE (CH) | 2002-11-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | KDM1A 4255/4885DCPS 1372/4885HPGDS 814/4885 |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | KDM1A 3501/4885DCPS 120/4885HPGDS 1499/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | KDM1A 4255/4885DCPS 1372/4885HPGDS 814/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | KDM1A 4255/4885DCPS 1372/4885HPGDS 814/4885 |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | KDM1A 3501/4885DCPS 120/4885HPGDS 1499/4885 |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | KDM1A 3501/4885DCPS 120/4885HPGDS 1499/4885 |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | FGFR1, MAPK1, FGF1 | KDM1A 3009/4885DCPS 1777/4885HPGDS 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.